Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

NCT00895466 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: PEP-223/CoVaccine HT

Sponsor

Pepscan Therapeutics

Collaborators

[object Object]